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ABSTRACT
Introduction: glioblastoma is a common condition associated with high morbidity and mortality; most of newly diagnosed patients will 
die within two years. The current standard therapy is maximal surgical resection followed by radiotherapy plus concomitant and adjuvant 
temozolamide. Objective: it is the aim of this review to evaluate how determinant surgical resection, radiotherapy and chemotherapy are 
to the outcome of patients with glioblastoma. Methods: a literature search is done to identify trials evaluating the outcome of adults with 
glioblastoma after being treated with surgery, radiotherapy or chemotherapy. The Oxford Centre for Evidence-based Medicine Levels of 
Evidence model is used to grade the quality of the available evidence. Results: 18 articles, reporting results of 15 studies were included. 
Five trials evaluated the effect of surgery in survival. Surgical provides as much as 4.9 months benefit in overall survival in cases in which 
complete resection is possible. A systematic review and four clinical trials reported that radiotherapy increases the mean overall survival 
in a range from three to five months. The European organization for research and treatment of Cancer and The National Cancer Institute 
of Canada Clinical Trials Group (EORT-NCIC) described in 2005 an increase of the survival by two - three months on patients receiving 
concomitant and adjuvant TMZ compared to patients receiving radiotherapy alone. Addittion of a novel chemotherapeutic agent seems 
to improve the outcome of patients compared to the current standard of care. Conclusion: surgery, radiotherapy and chemotherapy, each 
have a modest effect in the outcome of adults with glioblastoma. (MÉD.UIS. 2012;25(3):209-19).
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Cirugía, radioterapia y quimioterapia, ¿cómo cada uno contribuye al resultado 
del tratamiento en adultos con glioblastoma?
RESUMEN
Introducción: el glioblastoma es un tumor frecuente asociado a alta morbilidad y mortalidad, la mayoría de pacientes mueren antes 
de 2 años desde el diagnostico. La terapia estándar actual es resección quirúrgica máxima asociada a radioterapia mas temozolomida 
concomitante y coadyuvante. Objetivo: evaluar que tan determinantes son la resección quirúrgica, radioterapia y quimioterapia para el 
resultado del tratamiento en pacientes con glioblastoma. Métodología de búsqueda: una revisión de la literatura es hecha para identificar 
estudios que evalúen el resultado del tratamiento de adultos con glioblastoma tras ser tratados con cirugía, radioterapia o quimioterapia. 
El modelo de niveles de evidencia del Centro de Medicina basada en la evidencia de Oxford es usado para calificar la calidad de la evidencia 
encontrada. Resultados: 18 artículos, reportando resultados de 15 estudios son incluidos. Cinco estudios evalúan el efecto de cirugía en 
la sobrevida. La resección quirúrgica provee un beneficio tan alto como 4,9 meses en la sobrevida global en los casos en que la resección 
máxima es posible. Una revisión sistemática y cuatro ensayos clínicos han reportado que la radioterapia incrementa el promedio de 
sobrevida global en un rango de tres a cinco meses. La organización Europea para la investigación y manejo del Cáncer y el grupo de 
ensayos clínicos del instituto Nacional de Cáncer de Canadá (EORT-NCIC) describió en el 2005 un incremento en la sobrevida global en dos 
a tres meses en pacientes que reciben tratamiento concomitante y coadyuvante con temozolomida en comparación con pacientes que 
solo reciben radioterapia. La adición de uno de los nuevos agentes quimioterapéuticos parece mejorar el resultado del manejo comparado 
con el actual tratamiento estándar. Conclusión: el tratamiento quirúrgico, la radioterapia y la quimioterapia; cada uno tiene un efecto 
modesto en el resultado del tratamiento de pacientes con glioblastoma. (MÉD.UIS. 2012;25(3):209-19).
Palabras clave: Glioblastoma. Cirugía General. Radioterapia. Quimioterapia. Resultado del Tratamiento.
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introduCtion
Glioblastoma (GB) is a diffusely growing malignant 
brain neoplasm classified by the World Health 
Organization (WHO) as a Grade IV astrocytoma. It has 
a yearly incidence of 3 to 5 newly diagnosed cases per 
100.000 population and distinctive histological and 
clinical features that make it a particularly aggressive 
and devastating tumour1,2. The mean progression-free 
and overall survival (OS) times for patients treated 
with the current standard-of-care therapy (debulking 
surgery plus radiation plus concomitant and adjuvant 
temozolamide) within clinical trials are around 
7 and 15 months, respectively3. Selected patient 
populations with favourable prognostic factors 
have been reported to have a mean OS of 19 to 22 
months38. However, to date, not an effective curable 
treatment is available and more than 70% of patients 
will die in two years following diagnosis5. It is the aim 
of this review to evaluate how determinant surgical 
resection, Radiotherapy (RT) and Chemotherapy 
(CT) are in the outcome of patients with GB and how 
much each of those treatment modalities can add to 
the survival/outcome of the patients. 
Histopathologically, GB is a hyper cellular diffusely 
infiltrating tumor with nuclear atypia and mitotic 
activity; which is also associated with necrosis and/ 
or micro vascular proliferation. The majority of GB 
raises de novo as primary GB; however, anaplastic 
gliomas can evolve to secondary GB and represent 
10% of them. GB is the most aggressive and most 
studied tumor in the brain1 and most of the current 
knowledge comes from studies carried out in 
patients younger than 65 years. 
Current standard treatment for patients younger 
than 65 years newly diagnosed with GB is maximal 
surgical resection when feasible, plus 60 Gy of focal 
fractioned irradiation on daily fractions of 2 Gy for 
six weeks. This associated to concomitant CT with 
Temozolamide (TMZ), seven days per week from 
the first to the last day of CT (six weeks) followed 
by six cycles of five days of adjuvant TMZ every 28 
days. Biodegradable polymers, put into the tumour 
bed at surgery, can target residual tumour cells by 
gradually releasing carmustine over several weeks 
(gliadel) and is a therapeutic option approved for 
newly diagnosed High Grade Gliomas (HGG) 8.
Almost a half of the patients with GB are older than 
65 years, they are less responsive to treatment 
and have worst prognosis; the most common 
treatment for this group of age is hypo fractionated 
RT (40 Gy in 15 fractions). Depending on age and 
Karnofsky Performance Status (KPS), Debulking 
Surgery (DS) or concomitant and adjuvant CT can 
be considered10,11.
Despite optimal treatment, all malignant gliomas 
eventually recur; in those cases reoperation 
may be considered, and RT or CT have a modest 
controversial value12-4. Bevacizumab, an anti- Vascular 
Endothelial Growth Factor (VEGF) was approved in 
2009 as a single agent for recurrent GB in the US15,16. 
Different antiangiogenic and inmunomodulator 
drugs, inhibitors of integrin receptors and glutamate 
receptor blockers are being studied; they target 
specific pathways on tumoral pathogenesis and 
appear to be promising17-9.
MEthodS
A general search was performed in PubMed (United 
States National Library of Medicine) to find the 
most recent trials evaluating the outcomes of 
adults with GB after being treated with surgery, 
RT or CT. The following combination of words was 
used: “glioblastoma” or “grade iv gliomas” or 
“glioblastoma multiforme” or “high grade gliomas” 
and “surgery” or “resection” or “radiotherapy” or 
“chemotherapy” or “antineoplastic agents” and 
“outcome” or “treatment outcome”. The search 
was then limited to adults (19 + years) and published 
since January 2010.
The search retrieved 243 papers, their titles and 
abstracts were reviewed and 31 papers considered 
relevant were selected. Their full texts were 
reviewed and their references used to identify key 
past trials that support the current treatment and 
outcome of GB. Studies that included patients with 
low grade and/or grade III gliomas were excluded 
as well as studies that did not evaluate the effect of 
the treatments separately. The Oxford Centre for 
Evidence-based Medicine Levels of Evidence model, 
updated in 2009 (see Table 1) is used to grade the 
quality of the available evidence.
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Table 1. Oxford Centre for Evidence-based Medicine Levels of Evidence. 
Level Therapy/Prevention, Aetiology/Harm Notes
1a SR (with homogeneity*) of RCTs
*By homogeneity we mean a systematic review that 
is free of worrisome variations (heterogeneity) in the 
directions and degrees of results between individual 
studies.
1b
Individual RCT (with narrow Confidence 
Interval”¡)
“¡ Users can add a minus-sign “-” to denote the level of 
that fails to provide a conclusive answer because:
EITHER a single result with a wide Confidence Interval
OR a Systematic Review with troublesome heterogeneity.
Such evidence is inconclusive, and therefore can only 
generate Grade D recommendations
1c All or none§
§ Met when all patients died before the Rx became 
available, but some now survive on it; or when some 
patients died before the Rx became available, but none 
now die on it.
2a SR (with homogeneity*) of cohort studies
2b
Individual cohort study (including low 
quality RCT; e.g., <80% follow-up)
2c “Outcomes” Research; Ecological studies
3a
SR (with homogeneity) of case-control 
studies
3b Individual Case-Control Study
4
Case-series (and poor quality cohort and 
case-control studies §§)
§§ By poor quality cohort study we mean one that failed 
to clearly define comparison groups and/or failed to 
measure exposures and outcomes in the same (preferably 
blinded), objective way in both exposed and non-exposed 
individuals and/or failed to identify or appropriately 
control known confounders and/or failed to carry out a 
sufficiently long and complete follow-up of patients. 
5
Expert opinion without explicit critical 
appraisal, or based on physiology, bench 
research or “first principles”
Produced by: 63. Phillips et al, 1998. Updated by: 64. Howick, 2009.
rESultS
Preliminary search identified 31 papers reporting 
the outcomes of adults with GB after being treated 
with surgery, RT or CT. After detailed review 13 of 
these studies were found ineligible since they did 
not reported the effect of the treatment modalities 
separately or included patients with Grade II or III 
gliomas. 18 articles, reporting results of 15 trials 
were therefore eligible for inclusion; three papers 
reported subsequent analyses of trials whose 
primary results had been already published30,42,56.
The Table 2 summarizes the characteristics and main 
findings of five trials (six publications) evaluating the 
effect of surgery in the outcome of adult patients 
with GB. Not any of these trials reached the level of 
evidence 1. A systematic review (level of evidence 
1a) and four clinical trials were found describing the 
impact of RT in the outcome of GB patients (see 
Table 3). As shown in Table 4, a systematic review 
and meta-analysis (level of evidence 1a) failed to 
show any beneficial effect for the different CT 
regimens used before concomitant and adjuvant 
TMZ was described. The European organization for 
research and treatment of Cancer and The National 
Cancer Institute of Canada Clinical Trials Group 
(EORTNCIC) described in 2005 an increase in survival 
of patients receiving concomitant and adjuvant 
TMZ compared to patients receiving RT alone55. This 
findings have been reconfirmed with further analysis 
and follow up of the same cohorts30-56. Addition of 
a novel chemotherapeutic agent seems to improve 
the outcome of patients compared to the current 
standard of care3 (see Table 4).
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Table 2. Characteristics of trials  valuating the effect of surgery in the outcome of adult patients with GB.
Ref. Author, 
year
Treatment 
regimen
Patients characteristics Main results LOEn Age(r) KPS(r)
40. Vuorinen 
et al, 2003.
RT + Biopsy
RT + DS
13
10
70 (66–80) 
72 (67–79)
older than 65y
70
78
OS was 2.7 times longer 
(95% CI 1.004–7.568, p = 
0.049) after DS. There was 
no significant difference 
in PFS between these two 
treatments (p = 0.057)
2b
41. Stummer 
et al, 2006.
DS 
DS with 5-ALA
161
161
59 (30–73)
60 (23–73)
PFS was 19.9% (9·1–
30·7) higher in patients 
operated with 5-ALA than 
in the group operated 
under white light 
microsurgery (p=0·0003)
2b
42. Stummer 
et al, 2008.
DS 
DS with 5-ALA
Adjustment for 
bias  ref 41
122
121
Multivariate analysis to 
control prognostic factors.
Patients without residual 
tumor survived longer 
(16.7 vs. 11.8 mo, p < 
0.0001). Residual tumor, 
age, and KPS were 
significantly prognostic. 
Re-interventions occurred 
earlier in patients with 
residual tumor (6.7 vs. 9.5 
mo, p = 0.0582)
2b
45. Lacroix et 
al, 2001.
Single cohort
DS + RT+ CT
Evaluation of EOR
416 53 (14)
Significant OS advantage 
on resection of 98% or 
more (13 mo, 95% CI: 
11.4–14.6 mo), compared 
with 8.8 mo for resections 
of less than 98% (95% CI 
7.4–10.2 m; p < 0.0001).
Retrospective cohort 
(1993-1999)
3b
47. Ewelt et 
al, 2011.
Surgery (Biopsy 
or DS)
Surgery + RT
Surgery + RT+ 
CT
Evaluation of EOR
31
37
35
74.4
70.6
68.5
Older than 
65y
60
70
80
Complete resection 
group had a PFS of 10 
mo (95% CI: 5.6–14.4) vs. 
4.2 mo (95%CI: 3.8–4.6) 
for patients with partial 
resection (p<0.05). COX-
regression shows that the 
degree of resection was a 
significant factor for OS (p 
= 0.017).
Retrospective (2002-
2007)
3b
31. Sanai et 
al, 2011.
Single cohort
DS + RT+ CT
Evaluation of EOR
500 60 (21-90) 80 (20-100)
EOR were predictive of 
survival (p < 0.0001). 
Significant survival 
advantage with as little 
as 78% EOR. Stepwise 
improvement in survival 
was evident even in the 
95%–100% EOR range.
Retrospective cohort 
(1997-2009)
3b
5- ALA: 5-aminolevulinic acid, CI: Confidence Interval, CT: Chemotherapy, DS: Debulking Surgery, EOR: Extent of resection, KPS: Karnofsky 
Performance Status, LOE: Level of Evidence, mo: months, n: number of patients, (r): range, OS: Overall Survival, PFS: Progression free 
survival, RT=Radiotherapy, y: years.
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Table 3. Characteristics of trials evaluating the effect of Radiotherapy in the outcome of adult patients with GB.
Ref. 
Author,   
year
Treatment 
regimen
Patients characteristics
Main results LOE
n Age KPS
52. 
Laperriere 
et al, 2002.
Systematic 
review of 
various 
aspects of RT.
9 RCT in total including 6 
homogeneous trials of RT vs. no 
RT.
Six RCT detected a significant 
survival benefit favouring post-
operative RT compared with 
no RT (RR, 0.81; 95% CI, 0.74 
- 0.88, p, 0:00001). Two RCT 
demonstrated no significant 
difference in survival rates 
for WBRT versus more local 
fields. A RCT detected a small 
improvement in survival with 60 
Gy in 30 fractions over 45 Gy in 
20 fractions. 
1a
10. Keime-
Guibert et 
al, 2007.
Supportive 
care alone
Supportive 
care + RT
Patients 70 
years or older
42
39
73 y
75 y
The median OS for patients who 
received supportive care + RT 
was 29.1 weeks, as compared 
with 16.9 weeks for the 42 
patients who received supportive 
care alone. The HR for death in 
the RT group was 0.47 (95% CI, 
0.29 to 0.76; p = 0.002).
1b
51. 
Sandberg-
Wollheim 
et al, 1991.
PVC
PVC + RT
71
68
60 y
57 y
80 %
85%
Patients less than 50 y treated 
with PVC + RT had significantly 
longer survival (MTP: 81 wk, 
MST: 124 wk) than patients 
treated with PVC alone (MTP: 21 
wk, MST: 66 wk) after correcting 
for prognostic factors in a multi-
variate analysis (p = 0.037).  Age, 
KPS, and absence of extensive 
necrosis in the tumor were 
significant prognostic factors.
1b
49. 
Shapiro 
and Young, 
1976.
DS + Carms/
Vinc
DS + Carms/
Vinc + RT
16
17
60 y
58 y
71% ± 14%
57% ± 17%
MST of RT group was 30 wk, 
while that of no RT group was 
44.5 wk. The OS curves were not 
significantly different. RT do not 
increase morbidity
2b
50. Walker 
et al, 1980.
RT
Carmustine 
+ RT
Semustine
Semustine 
+ RT
111
118
Multi-arm collaborative study. 
61. Walker et al, 1978. and 
62. Kristiansen et al, 1981. are 
publications based on the same 
study. Significant survival benefit 
favouring CT+RT compared 
with CT alone. No significant 
difference in survival between 
RT alone and CT+RT (data not 
shown).
2b
Carms/Vinc: Carmustine + Vincristine, CI: Confidence Interval, CT: Chemotherapy, DS: Debulking Surgery, HR= hazard ratio,  KPS: Karnofsky 
Performance Status, LOE: Level of evidence, MST: Mean Survival Time, MTP: Mean time to progression, n: number of patients, OS: Overall 
Survival, PVC: procarbazine, vincristine, and lomustine (CCNU), RCT: Randomized Controlled Trials, RR: Risk ratio, RT=Radiotherapy, WBRT: 
Whole brain radiotherapy, wk: weeks, y: years.
Rojas a MéD.UIS. 2012;25(3):209-19
214
Table 4. Characteristics of trials evaluating the effect of chemotherapy in the outcome of adult patients with GB.
Ref. Author, 
year
Treatment 
regimen
Patients characteristics
Main results LOE
n age
54. Stewart 
2002.
SR and meta-
analysis of RT 
alone vs. RT + 
CT* (no TMZ)
Data from 3004 patients 
from 12 RCT 
(1 no published)
Modest prolongation of OS associated 
with CT, HR: 0·85 (95% CI 0·78–0·91, 
p<0·0001) or a 15% relative decrease 
in the risk of death. This effect is 
equivalent to an absolute increase in 
1y survival of 6% (95% CI 3–9) from 
40% to 46%. 
1a
55. Stupp et 
al 2005.
EORT-NCIC
RT
RT + TMZ
286
287
57 (23-71)
56 (19-70)
At a median follow-up of 28 mo, the 
median survival was 14.6 mo with 
RT+TMZ and 12.1 mo with RT alone. 
The unadjusted HRfor death in the 
RT+TMZ group was 0.63 (95% CI, 
0.52 to 0.75; p<0.001). Two-year 
survival rate was 26.5% with RT+TMZ 
and 10.4 % with RT alone.
1b
30. Stupp et 
al, 2009.
EORT-NCIC
RT
RT + TMZ
5 years 
analysis of 
EORTC-NCIC 
trial55
286
287
57 (23-71)
56 (19-70)
OS was significantly higher at 2, 3 4 
and 5 years in patients treated with 
RT +TMZ compared to RT alone (HR 
0·6, 95% CI 0·5–0·7; p<0·0001). A 
benefit of combined therapy was 
recorded in all clinical prognostic 
subgroups, including patients aged 
60–70 y. Methylation of the MGMT 
promoter was the strongest predictor 
for outcome and benefit from TMZ.
1b
56. 
Mirimanoff 
2006.
EORT-NCIC
RT
RT + TMZ
RPA of 
EORTC-NCIC55
286
287
57 (23-71)
56 (19-70)
In RPA the groups with better 
prognosis (class III and IV), the survival 
advantage remained significant 
(p <0.0001). In RPA the groups of 
patients with worst prognosis (class 
V), the survival advantage of RT+TMZ 
was of borderline significance 
(p=0.054).
1b
3. Grossman 
et al, 20103. 
EORTC-
NABTT
DS+RT+TMZ 
(HC)
DS+RT+TMZ 
DS+RT+TMZ 
+ NA
287
49
244
56 (19-70)
58 (29-69)
55 (21-70)
Median, 12-mo, and 24-mo survival 
rates for the EORTC patients (n = 287) 
and the comparable NABTT patients 
receiving RT + TMZ + NA (n = 244) 
are 14.6 vs. 19.6 mo, 61% vs.81%, 
and 27% vs. 37%, respectively. This 
represents a 37% reduction in odds of 
death (p < 0.0001) through 2 years of 
follow-up.
2b
*Includes different doses and combinations of Carmustine, Lomustine, Dicarbazine, Mitolactol, Bleomycin, Nimustine, but no TMZ.
CI: Confidence Interval, CT: Chemotherapy, DS: Debulking Surgery, EORT-NCIC: European organization for research and treatment of 
Cancer and The National Cancer Institute of Canada Clinical Trials Group, HC: Historical Cohort, HR= hazard ratio, LOE: Level of evidence, 
mo: month, n: number of patients, NA= New Agent (talampanel or poly-ICLC or Celengetide), NABTT: New Approaches to Brain Tumour 
Therapy consortium, OS: Overall Survival, RCT: Randomized Controlled Trials, RPA: recursive partitioning analysis,  RT=Radiotherapy, SR: 
Systematic review, TMZ=Temozolamide, y: years.
OS and Progression Free Survival (PFS) were the most 
commonly used outcome measures. OS is considered 
the gold standard end point for patients with HGG; 
it is thought to prove an objective and unequivocal 
clinical benefit particularly useful in GB given its 
short life expectancy. However, OS can be affected 
by the treatment start time, factors unrelated to 
the studied therapy, and salvage therapies used 
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at recurrence20,21. PFS is the time from treatment 
initiation to progression or death from any cause and 
reflects the treatment effect without influences from 
recurrence therapies22. Radiographic methods used 
to determine progression in the case of PFS and the 
assessment of overall radiographic response become 
problematic or even unreliable after the introduction 
of new therapies and the description of pseudo 
progression. The use of corticosteroids and radiation 
can modify the permeability of tumoral blood vessels 
and therefore the correlation between tumour 
enhancement and tumour evolution23,24. Particularly 
important is pseudo progression; an increase in 
contrast enhancement and peritumoral edema 
sometimes associated to neurologic worsening 
described after RT plus TMZ25,26; or pseudo response, 
an apparent improvement in contrast enhancement 
due to diminished vascular permeability described 
after treatment with bevacizumab. Even when 
those changes do not reflect the real effect of 
the treatment, they modify the radiographic 
features that could be used to evaluate response 
or progression27. Nowadays, not any imaging based 
method can reliably assess progression or response 
in HGG; the recently defined Revised Assessment 
in Neuro-Oncology (RANO) criteria are expected to 
resolve these issues20.
diSCuSSion
Much has been trialled to improve the outcome of 
patients with GB; however, no current therapy is 
capable of modifying the process of the disease. 
Prolongation in survival and improvement in quality 
of life can be reached using the best available 
treatment. The first papers published about GB 
reported a survival of seven weeks in patients 
without any treatment; similar to the recent findings 
of two months on elderly patients who did not 
receive any treatment28,29. In the last three decades, 
implementation of DS, RT and CT has prolonged 
the survival of patients with GB to 12-18 months3,30. 
The aforementioned benefit on survival is not seen 
in all patients receiving optimal treatment, but 
some patients have been clearly identified to be no 
responsive. Several factors have been associated 
to either poor response or good prognosis29-37. 
Those factors are currently thought to be more 
important to outcome that the treatment by itself. 
For instance, age and KPS are such strong outcome 
predictors that patients older than 70 years and 
low KPS are usually treated with supportive care 
or RT alone29. The appearance of the tumour in 
the scans, its enhancement, size and location are 
important for surgery planning and determine 
the possible extent of resection without new 
neurological deficit31. The histological analysis of 
the tumour and WHO classification, do not entirely 
correlate the outcome due to the heterogeneity 
of malignant gliomas. However, new molecular 
analyses of the tumour seem to provide powerful 
prognostic factors. For instance, the methylation of 
DNA repair enzyme O-6 Methyl Guanine-DNA Methyl 
Transferase (MGMT) in GB is predictive of improved 
prognosis and better response to TMZ32,33. Mutation 
in codon 132 of the isocitrate dehydrogenase 1 (IDH 
1) gene can help to diagnose secondary GB and 
confer a prognostic advantage on patients with 
anaplastic astrocytoma34,35. Also, 1p/19q co-deletion 
is an indicator of anaplastic oligodendroglioma 
vulnerability to a wide range of therapies including 
PVC36,37. These molecular features allow a better 
classification of tumours and aid in the differentiate 
patients who should receive aggressive initial 
treatment from those who do well regardless of 
the given treatment, thus allowing decision making 
based on side effects38. Nonetheless, given the 
short list of effective therapies, there is a long way 
to get the entire utility of those markers; such as, 
that patients with non-methylated MGMT promoter 
tumours who are known to be poor responders 
to TMZ are still treated with it because there is no 
better option available39. 
SurgEry
Surgical approach to patients with GB is critical since 
it reduces the symptoms of increased intracranial 
pressure and mass effect, and provides tissue for 
histologic classification and molecular evaluation, 
which allows classification, prognosis and therapeutic 
approach. Further than allowing histological 
diagnosis and reducing mass effect, surgical 
resection effect on survival is minimal and difficult to 
evaluate due to ethical issues on randomization of 
non-surgical management or subtotal resection. One 
prospective study randomized biopsy or DS on 30 
patients older than 65 years with radiologic evidence 
of malignant gliomas and found a modest survival 
benefit (2.9 months) on patients with tumour 
resection; however, this was a small and unblinded 
trial on patients with poor prognosis40. Stummer 
et al described that GB patients who underwent 
complete resection of contrast enhancing tumour 
under fluoroscopic guide with 5-aminolevulinic acid 
had a significantly higher PFS at six months (41%) than 
patients with less extensive resection done under 
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conventional white light microsurgery (21.1%)41. A 
follow up of the same study controlled different bias 
and variables and concluded a 4.9 months benefit 
of complete resection42. Several trials have reached 
the same conclusion and there is an established 
consensus that total resection improves OS43,44. As 
total resection is not always possible, it has been 
evaluated what is the minimal resection needed to 
have a benefit. Lacroix and colleagues studied the 
effect of Extent Of Resection (EOR) in patients with 
GB and concluded a longer survival in patients who 
had a resection of more than 98% of the tumour 
especially if age, KPS score and primary imaging 
features were favourable45; it became a paradigm 
in neurosurgery and clinical decisions were for long 
time based in that retrospective, non-randomized 
trial. Recently, 500 adults consecutively diagnosed 
with GB were evaluated to see the role of EOR on 
survival; a significant benefit was seen with as low 
as 78% and the benefit increased proportionally with 
the EOR31. This has been also proven in the elderly 
population with GB46,47.
The benefit of surgery is related to better response 
to adjuvant therapies and does not come solely from 
the surgery; patients with complete resection and 
TMZ have significantly higher OS than incomplete 
resection plus TMZ42. Surgery is of paramount 
importance for treatment of GB since it allows 
histological diagnosis and decompression, has a 
modest benefit in OS that increases proportionally 
with the EOR and seems to improve the response to CT. 
New surgical technologies such as neuronavigation, 
intraoperative MRI, functional MRI, intra operative 
mapping, and fluorescence guided surgery are being 
used to improve safety and EOR43,48.
radiothErapy
RT was firstly described as increasing the mean OS 
in a range from three to five months49-51. Laperriere 
et al conducted a systematic review and found a 
significant survival benefit favouring post-operative 
RT with a risk ratio of 0.81 (CI 95 % 0.74-0.88). No 
significant difference between whole brain and 
local radiation was found, and a modest benefit on 
survival on 60 Gy divided in 30 fractions over 45 Gy 
in 20 fractions was described52. No benefit from RT in 
patients older than 70 was found. Not much research 
has been done on the evaluation of RT in GB over the 
last ten years, and the evidence found comes from 
some works in elderly patients who are still thought 
no to benefit from RT or CT. A multi-institutional trial 
randomized 85 subjects with GB from 10 institutions 
to RT plus supportive care or supportive care 
alone and found that patients in the RT group lived 
three months longer10. Those results were recently 
reconfirmed by a large population based study which 
proved that an abbreviated course of RT with a total 
dose of 40 Gy in 15 fractions is as effective as the 
standard scheme29. It is now widely accepted that 
RT prolongs the survival of young patients with GB 
in three to five months and around two months in 
patients older than 70 years10,53.
ChEMothErapy
In 2002 the Glioma Meta-analysis Trialist (GMT) 
group published the results of a meta-analysis of 12 
randomized trials that failed to prove CT useful in 
patients with GB54. However, the history of CT for 
GB hanged in 2005 when the European Organization 
for Research and Treatment of Cancer (EORTC) 
and the National Canada Institute of Cancer (NCIC) 
published a trial on 573 patients from 85 centres 
randomized to RT alone or RT plus concomitant 
and adjuvant TMZ for newly diagnosed GB. The 
median OS was 2.5 months longer in the group 
with RT plus TMZ, and the two-years survival of 
26.5% on subjects with RT plus TMZ was significantly 
higher than 10.4% in the group with RT alone55. 
Those findings were complemented with the five 
year follow up of the same patients showing a 
sustained benefit of RT plus TMZ over time in all 
of the prognostic groups30. Furthermore, as pre-
treatment prognostic factors can be more relevant 
to the outcome than the therapy, the EORTC study 
was recently tested with a recursive partitioning 
analysis; the overall prognostic significance was 
retained between the different recursive groups; 
and as expected, particularly strong in patients with 
favourable prognostic factors56. Nowadays, new 
treatments for GB are compared with postsurgical 
RT plus TMZ and new chemotherapeutic agents 
are evaluated in addition to that gold standard. 
Anaplastic oligodendroglioma was the first 
described malignant brain tumor to be uniquely 
chemo sensitive as PCV was demonstrated to be 
effective in those patients57. Later, CT with PCV and 
TMZ were shown to be equally valuable to improve 
the outcome, although TMZ showed a better safety 
profile6,44,58.
Recently, the New Approaches to Brain Tumors 
Therapy (NABTT) consortium evaluated the addition 
of new chemotherapeutic agents to RT plus TMZ 
in patients with GB. The addition of talampanel, 
poly-ICLC or cilengetide to the standard treatment 
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Research on surgery, RT and CT for GB in the elderly 
and in patients with low KPS is rapidly evolving. 
However, some patients are still found to have only 
biopsy and support care or RT alone. This allows an 
individual evaluation of each treatment modality. 
Patients with different kinds of treatments can be 
conveniently stratified and the predictive factors 
can be controlled to evaluate the independent 
effect of an intervention. As can be seen in Table 5, 
two retrospective trials on contemporary patients 
assessed the individual value of surgery, RT and CT 
and confirmed that all of them actively contributed 
to an improved outcome in patients with GB (Level 
of evidence 3b)59,60. It is evident that the population 
in the study by Marina et al had a worse prognosis, 
but the proportion of improvement was similar in 
both studies, showing again that surgery, RT and 
CT, each have a modest but significant effect in the 
outcome of adults with GB.
increased the OS from 14.6 months as described 
in the EORTC study in 2006 to 19.6 months in the 
new agent added group3. The trial was designed as 
a four single-cohorts study with historical controls 
accrued internationally from 2000 to 2002 and not 
strong enough to support the addition of a novel 
agent to the standard treatment. However, it is 
significant that it shows how CT has contributed to 
improve the outcome of these patients. For instance 
patients treated with postsurgical RT in 2000 
had a mean OS of 12 months and only 8% of them 
survived for more than two years40; while the mean 
OS of patients treated in 2010 with postsurgical 
RT plus TMZ plus a new chemotherapeutic agent 
was 19.6 months and 37% of them lived for more 
than two years3. Although part of that benefit 
must be due to improvement in general care of 
oncologic conditions; most of it can be reliably 
attributed to CT.
Table 5. Survival of patients with poor prognosis (elderly patients and/or low performance status) in two studies with treatment stratification. 
Treatment stratification
59. Kushnir and Tzuk-
Shina. 2011
60. Marina et al.
2011
n. Mean OS n. Mean OS
All the patients 74 8.9 mo 74 2.3 mo  (0.2-48 mo)
Surgical 
stratification
Biopsy/no surgery 32 5.22 mo 38 1.6 mo
Debulking surgery 42 11.83 mo 36 5.8 mo
Radiation 
treatment 
Partial or no  RT 24 4.09 mo 22 1.6 mo
RT 50 11.31 mo 52 5.2 mo
Chemotherapy 
stratification
No Chemotherapy 39 5.89 mo 54 1.7 mo
chemotherapy 35 12.4 mo 20 9.8 mo
mo: months, n: number of patients,  OS: overall survival, RT: Radiotherapy.
ConCluSion
In the last three decades, the implementation of DS, 
RT and CT has prolonged the survival of patients with 
GB to 12-18 months. Although the outcome seems to 
be more related to predictive factors such as age, KPS 
and molecular profile of the tumor, each modality 
of treatment has shown to improve the outcome 
by itself. Surgery is determinant since it reduces 
the symptoms of increased intracranial pressure 
and mass effect and provides tissue for histologic 
and molecular analysis. Surgery provides a modest 
benefit of three months OS in the case of GB and 
as much as 4.9 months when complete resection is 
possible. RT has been found to increase the mean OS 
in a range from three to five months and has shown 
itself useful in the elderly population. Concomitant 
and adjuvant TMZ increases the OS by two-three 
months and some studies suggest a further two 
month increase in OS when a new chemotherapeutic 
agent is added to postsurgical radio-chemotherapy. 
Surgery, RT and CT, each have a modest effect in 
the outcome of adults with GB; nonetheless, when 
used together as the best available treatment, they 
considerably improve the outcome. Future research 
must focus on evaluation of molecular outcome 
predictors and development of targeted agents that 
can impact the natural history of the disease.
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